US › Healthcare

Serina Therapeutics Inc (SER)

US · Healthcare · Biotechnology

$2.22+2.78%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-6.4M

EPS

$-0.55

EPS estimate

$-0.35

EPS came in at -0.55 against a street estimate of -0.35 — a miss of 57.1%.

Key statistics

Market cap

$62.2M

Forward P/E

0.0

P/B

3.01

Book value

$0.74

EPS (TTM)

$-1.87

52-week high

$5.83

52-week low

$1.22

50-day MA

$2.37

200-day MA

$2.25

Beta

0.09

Analyst view

Analysts rate Serina Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $9.50.

Shareholding

Insiders

50.75%

Institutions

5.55%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Serina Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.